Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | IL1RN | P18510 | 1/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27889027 | 0.93 | ALDH1A1 (0.67) | HDAC1HDAC8ALDH1A1POLBGAA | |
| SCHEMBL5202198 | 0.87 | HDAC1 (0.71) | HDAC1HDAC8ALDH1A1GAAMEN1 | |
| SCHEMBL27884380 | 0.86 | KMT2A (0.61) | HDAC1HDAC8ALDH1A1POLBGAA | |
| SCHEMBL8074277 | 0.86 | ALDH1A1 (0.74) | HDAC1HDAC8ALDH1A1POLBGAA | |
| SCHEMBL14812106 | 0.86 | HDAC8 (1.00) | HDAC1HDAC8ALDH1A1MEN1KMT2A | |
| SCHEMBL397676 | 0.84 | HDAC1 (0.68) | HDAC1HDAC8ALDH1A1POLBMEN1 | |
| SCHEMBL27430787 | 0.84 | PGR (0.71) | HDAC1HDAC8ALDH1A1POLBGAA | |
| SCHEMBL8249490 | 0.84 | HDAC1 (0.76) | HDAC1HDAC8ALDH1A1POLBMEN1 | |
| SCHEMBL31681345 | 0.83 | ALDH1A1 (0.63) | HDAC1HDAC8ALDH1A1POLBGAA | |
| SCHEMBL2822371 | 0.83 | MEN1 (0.67) | HDAC1HDAC8ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7160887-B1 | Aromatic amine derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060134130-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-7005141-B2 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES INC. (US) | 2006-02-28 | — | — | US | disclosed |
| CN-1726044-A | Compositions and methods for enhancing mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARM CO (US) | 2006-01-25 | — | — | CN | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5709861-A | PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0812212-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996021464-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134130-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | HDAC1 2962/4885HDAC8 1441/4885ALDH1A1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.